Liquidia Corp — Form 8-K
Filed September 30, 2026 · analyzed by the 8-K Agent
8-K
▼ Likely negative
significance 76/100
What the filing says
U.S. District Court for Delaware found that claims 1 and 14 of United Therapeutics' U.S. Patent No. 11,826,327 are valid and infringed by Liquidia's YUTREPIA (treprostinil) inhalation powder; four other asserted claims were ruled invalid. Parties must submit proposed remedies within one week. UTHR is seeking injunctive relief that could restrict or block YUTREPIA's market availability, though Liquidia plans to appeal and remove the PH-ILD indication from the label.
Why this rating
Partial patent loss on lead product (launched 2025) threatens major revenue stream; injunction risk is material to ~$847M market-cap company; label restriction or market block would be transformational damage.
Price action (we called it negative)
before filing · preread $30.29 | at our read pending | +10 min pending | +30 min pending | +1 hr pending | +4 hrs pending |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from September 30, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.